Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer

AIMS: Rilotumumab is a fully human monoclonal antibody investigated for the treatment of MET‐positive gastric cancer. The aim of this study was to evaluate the potential pharmacokinetic (PK)‐based drug–drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X)....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Zhang, Yilong, Kuchimanchi, Mita, Zhu, Min, Doshi, Sameer, Hoang, Tien, Kasichayanula, Sreeneeranj
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Pharmacokinetics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5401968/
https://ncbi.nlm.nih.gov/pubmed/27966237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13179
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky